The lack of association between PADI4_94 or PADI4_104 polymorphisms and RF, ACPA and anti-PAD4 in patients with rheumatoid arthritis

Marek Ciesla*, Bogdan Kolarz & Dorota Darmochwal-Kolarz

Rheumatoid arthritis (RA) is a chronic autoimmune disease that leads to chronic inflammation of synovial tissue, ultimately causing joint damage, disability, and premature mortality. The peptidylarginine deiminase (PAD) family of proteins is involved in the production of anticitrullinated peptide antibodies (ACPA), which are clinically relevant markers of RA. ACPA recognizes citrullinated proteins generated mainly by PAD4. Polymorphisms of the PADI4 gene have been associated with RA in Asian populations, but in Europeans these associations are still difficult to estimate. A total of 147 subjects, 122 patients with RA, 52 ± 12.3 aged, 84.4% women and 25 healthy controls, 53 ± 8.4 aged, 72% women were enrolled in the study. Two single nucleotide polymorphisms (SNPs) of the PADI4 gene (PADI4_94, rs2240340 and PADI4_104, rs1748033) were genotyped using a real-time polymerase chain reaction. Genetic models (co-dominant-1 and 2, dominant, over-dominant, and recessive) were applied to find the associations between genotypes and ACPA as well as PAD4 antibodies (anti-PAD4) levels. We found no relationship between the distribution of genotypes in different genetic models and the levels of anti-PAD4, ACPA and RF antibodies. There were also no differences with respect to the haplotypes. Genetic variants PADI4_94 and PADI4_104 may not be clinically relevant as prognostic factors in patients with established RA.
Single nucleotide polymorphisms (SNPs) have been related to susceptibility to RA. The first and most significant genetic locus associated with the development of the disease are class II human leukocyte antigen (HLA) genes and other non-HLA genes, including: \textit{PAD4}, \textit{IL23R}, \textit{PTPN22} and others. Previous studies have shown an association between SNPs in \textit{PAD4} gene and susceptibility to RA mainly in Asian population, but the results are inconsistent amongst Caucasians.

An SNP with rs2240340 \textit{G} \textgreater \textit{A}, \textit{PAD4} \_94, is located in the intronic region of the \textit{PAD4} gene with a minor allele frequency in the European population (HapMap CEU) of 0.43. The association between \textit{PAD4} \_94 and susceptibility to RA in the Japanese population was reported with an odds ratio (OR) of 1.22. On the contrary, this association has not been confirmed with respect to the European population. A SNP with rs1748033 \textit{T} \textgreater \textit{C} (\textit{A} \textgreater \textit{G}), \textit{PAD4} \_104, is located in the 5’ untranslated region with a minor allele frequency in the European population (HapMap CEU) of 0.36. The nucleotide change \textit{T} \textgreater \textit{C} is responsible for the synonymous leucine change at codon 117. Some studies have shown the association between the aforementioned SNP and susceptibility to RA. In the Japanese population, the higher risk of RA development was related especially to male smokers. No relationship has been found between \textit{PAD4} gene and RA in Caucasians.

The present study shows the lack of association between anti-PAD4 antibody levels and the prevalence of genotypes in patients with RA, taking into account the different genetic models. The aim of this study was to investigate the association between the two polymorphisms \textit{PAD4} \_94 (rs2240340) and \textit{PAD4} \_104 (rs1748033) and the levels of anti-PAD4 antibodies in patients with RA, taking into account the different genetic models.

**Results**

The prevalence of the \textit{PADI4} \_94 and \textit{PADI4} \_104 minor allele (for a total of 122 RA patients) was 0.48: \textit{GG} = 36 (29.3%), \textit{GA} = 56 (45.9%), \textit{AA} = 30 (24.6%) and 0.36: \textit{GG} = 49 (40.2%), \textit{GA} = 58 (47.5%), \textit{AA} = 15 (12.3%), respectively. The distribution of genotypes in patients with RA was consistent with the Hardy–Weinberg equilibrium (\textit{p} = 0.38 and 0.73, respectively). Regarding \textit{PADI4} \_94, in the anti-PAD4 positive RA group (\textit{n} = 68), the prevalence of genotypes was as follows: \textit{GG} = 17 (25%), \textit{GA} = 33 (48.5%), \textit{AA} = 18 (26.5%). In the anti-PAD4 negative group (\textit{n} = 54) there were 19 homozygotes \textit{GG} (35.2%), 23 heterozygotes \textit{GA} (42.6%), and 12 homozygotes \textit{AA} (22.2%). The distribution of \textit{PADI4} \_94 genotypes in anti-PAD4 positive patients with RA was as follows: \textit{GG} = 28 (41.2%), \textit{GA} = 33 (48.5%) and \textit{AA} = 7 (10.3%). In the anti-PAD4 negative group there were 21 (38.9%) carriers of \textit{GG} genotype, 25 (46.3%) carriers of \textit{GA} and 8 carriers of \textit{AA} (14.8%). Genotype distribution for the following groups: ACPA positive vs. ACPA negative, and RF positive vs. RF negative can be found in Supplementary Table S1.

In relation to \textit{PADI4} \_94 in the co-dominant model there was no difference in the level of anti-PAD4 antibodies (\textit{p} = 0.52) between carriers of the \textit{GG} genotype—median: 558.17 U/ml [interquartile range: 368.94–1002.15] and carriers of the \textit{GA} genotype 699.74 [368.68–1372.55].

The co-dominant 2 model (\textit{GG} vs. \textit{AA} genotypes) also showed no differences: 558.17 [368.94–1002.15] vs. 925.55 [278.16–1815.44], \textit{p} = 0.54. The dominant model (\textit{GA} + \textit{AA} vs. \textit{GG}) showed a lack of association (\textit{p} = 0.47) between anti-PAD4 level and genotype distribution—727.81 [339.36–1398.8] vs. 558.17 [368.94–1002.15], respectively. There was no relationship to the over-dominant model (\textit{GA} vs. \textit{GG} + \textit{AA}, \textit{p} = 0.79): 699.74 [368.68–1372.55] vs. 679.16 [337.02–1286.2]. The recessive model (\textit{AA} vs. \textit{GA} + \textit{GG}) also did not show an association (\textit{p} = 0.66) between anti-PAD4 levels and genotype distribution—925.55 [278.16–1815.44] vs. 677.9 [368.68–1259.8], accordingly.

In relation to \textit{PADI4} \_104 in the co-dominant 1 model (\textit{GG} vs. \textit{GA}), the subgroups had similar levels of anti-PAD4 antibodies: 706.58 [412.17–1286.2] vs. 681.39 [336.22–1323.4]; \textit{p} = 0.82.

In the co-dominant 2 model (\textit{GG} vs. \textit{AA}) there was no difference in the levels of anti-PAD4—706.58 [412.17–1286.2] vs. 564.96 [271.26–1910]; \textit{p} = 0.85.

Dominant and over-dominant models (\textit{GG} + \textit{GA} vs. \textit{GG} and \textit{GA} vs. \textit{GA} + \textit{AA}, respectively) also showed a significant association between the groups: 680.86 [325.98–1288.1] vs. 706.58 [412.17–1286.2]; \textit{p} = 0.8 and 681.39 [336.22–1323.4] vs. 691.49 [405.61–1372.55]; \textit{p} = 0.86, accordingly. The recessive model (\textit{AA} vs. \textit{GG} + \textit{GA}) did not show differences in anti-PAD4 levels—564.96 [271.26–1910] vs. 681.92 [346.2–1286.2]; \textit{p} = 0.93. Furthermore, genetic models did not show differences in the levels of other antibodies (ACPA and RF) between seropositive and seronegative patients with RA. For details, please refer to Supplementary Tables S2–S8.

Haplotype analysis was performed using the LDhap tool (available from https://ldlink.nci.nih.gov/?tab=ldhap). Between \textit{PADI4} \_94 and \textit{PADI4} \_104, 3 functional haplotypes were estimated in the European population: \textit{G}, \textit{A}, \textit{A}, and \textit{A}. G. In our study, the \textit{A} \_G haplotype was represented by 3 cases, therefore it was omitted in further analysis. There were no associations between anti-PAD4, ACPA and RF levels and haplotypes (\textit{p} = 0.99, \textit{p} = 0.36 and \textit{p} = 0.6, respectively).

**Discussion**

The present study shows the lack of association between anti-PAD4 antibody levels and the prevalence of genotypes with respect to different genetic models (codominant, dominant, over-dominant, and recessive) for both single nucleotide polymorphisms: \textit{PADI4} \_94 (rs2240340) and \textit{PADI4} \_104 (rs1748033).

A total of five PAD enzyme isoforms were found, in which PAD2, PAD3, and PAD4 were responsible for autoimmune reactions in RA. PAD4 is the most characterized. It is found mainly in the nucleus of white blood cells, and its overexpression has been found specifically in neutrophils and monocytes in synovial tissue. SNPs in the \textit{PADI4} gene have also been linked to the development of RA in some populations, especially Asian, but amongst Europeans the results are inconclusive. The new light on this issue was presented in the study conducted by...
Lee et al. 14. They showed that the variants PADI4_94 and PADI4_104 may be associated with susceptibility to RA in Asian and Caucasian populations when homozygous contrast was used. Consequently, we assumed that the use of genetic models may be helpful in determining the relationship between SNPs and antibody levels. In addition to genetic factors associated with RA, epigenetic changes have been reported in the PADI4 gene. Increased methylation in the promoter region was associated with lower disease activity, lower levels of ACPA, and anti-PAD4 antibodies 20.

Anti-PAD4 antibodies are associated with structural damage of joints and a more severe clinical outcome; therefore, their evaluation may be of prognostic importance 25. The specificity of them was reported to be greater than 95% in patients with RA. Antibodies are not specific to RA, as they have been found in other rheumatic diseases, e.g. SLE, but at lower levels 27. Anti-PAD4 antibodies have an incidence ranging from 16.2 to 50% of RA patients and may be related to the study population and duration of the disease 12,24,28–30. In this study, anti-PAD4 positivity was approximately 56% and may be associated with the duration of the disease (the median duration of the disease was 10 years) and the relatively small size of the group derived from one medical center. Moreover, Reyes-Castillo et al. 24 showed that patients with RA, with the disease lasting more than 2 years (mean duration of the disease was 8 years), had higher levels of anti-PAD4 antibodies compared to patients with disease duration of less than 2 years.

We found no association between anti-PAD4 antibody levels and genotypes, which is consistent with recent reports 12,24. In the study conducted by Reyes-Castillo et al., three SNPs were tested: PADI4_89 G>A (rs11203366), PADI4_90 T>C (rs11203367) and PADI4_92 G>C (rs874881). They found no association between the susceptibility haplotype GTG and the levels of anti-PAD4 antibodies; however, carriers of the susceptibility haplotype demonstrated higher ACPA levels. On the other hand, a study conducted by Harris et al. 31 demonstrated an association between a susceptible haplotype and anti-PAD4 levels with an odds ratio (OR) of 2.59. They genotyped the same three SNPs as Reyes-Castillo et al. Furthermore, when diplotype analysis was applied, carriers of heterozygous genotypes, including both nonsusceptible and susceptible haplotypes, had increased antibody levels compared to patients homozygous in haplotype 1, with an OR of 4.02. It must be emphasized that the mean duration of the disease in RA patients (overall) was longer than in the study conducted by Reyes-Castillo et al. and was 12.5 years. In addition, a study by Guderud et al. 12 was focused on the relationship between autoantibody level and genetic factors. They found no association between PADI4 rs2240340 and rs1635579 and anti-PAD4 autoantibodies. On the other hand, Guderud et al. 12 demonstrated that ACPA-negative patients vs. healthy controls showed a weak association with RA morbidity in relation to the two PADI4 SNPs: rs2240340 (PADI4_94) and rs1635579. Both polymorphisms mentioned turned out to be associated with double negative patients with RA (ACPA negative and anti-PAD4 negative). The authors suggest that genetic risk factors should only be evaluated in relation to ACPA status, as also suggested in a previous study 24. In this study, we did not confirm the association between SNPs and ACPA, anti-PAD4 and RF antibody levels. Current diagnostic criteria include serological markers, such as RF and ACPA 1. ACPA shows positivity in the range of 60–80% of RA with a specificity in the range 90–95% 32. In our cohort, less than 15% of patients with RA were ACPA negative. As previously reported, ACPA has been associated with a higher risk of developing RA in healthy individuals and may occur before the clinical symptoms of RA. ACPA-positive RA patients have a less favorable prognosis, including more complicated structural damage and a worse response to therapy. In the present study, no relationship was found between ACPA concentration and genotypes, also in different genetic models.

We did not confirm the hypothesis that carriers of the genetic variants may have a different (higher) autoantibody status and therefore a less favorable clinical outcome, as previously suggested. The limitation of the study was the small size of the group, notably in the context of genotyping. Further investigations in a larger cohort of patients are necessary to confirm our data, especially the conclusions regarding ACPA-negative patients should be confirmed in the wider population. We believe that in relation to established RA, genetic testing, especially including common SNPs, may not be helpful. It seems to be helpful to measure and compare the anti-PAD4 levels with genotypes during the RA diagnosis or in pre-RA.

Methods
A total of 147 subjects, 122 patients with RA, 52 ± 12.3 aged, 84.4% women and 25 healthy controls, 53 ± 8.4 aged, 72% women were enrolled in the study. Written informed consent was obtained from every participant before entering the study and all research was performed in accordance with relevant guidelines. The study was conducted in accordance with the Declaration of Helsinki and the Ethics Committee of the Medical University of Lublin approved the study (protocol number KE-0254/7/2016). The characteristics of the individuals are presented in Table 1.

Whole blood was collected and stored at -80 °C until analysis. DNA was extracted from 200 μl of sample according to the manufacturer’s protocol using the GeneMATRIX Quick Blood DNA Purification Kit (Eurx, Poland).

Genotypes of PADI4_94 with rs2240340 (assay ID: C__16176717_10, Thermo Fisher Scientific, USA) and PADI4_104 with rs1748033 (assay ID: C__7541083_1, Thermo Fisher Scientific, USA) were evaluated using TaqMan Genotyping assays and the Endpoint Genotyping module of the COBAS z480 Real-Time PCR System (LightCycler 480 SW, version 1.5.1.62 SP2–UDF v.2.0.0, Roche, Germany). Antibodies levels were previously evaluated and the methodology was described 33. Briefly, ACPA and RF cut-offs were estimated according to manufacturer’s recommendations. Anti-PAD4 positivity was evaluated based on results in a control group as below 95th percentile. Additionally for PAD4 a receiver operating characteristic (ROC) curve with cut-off value (Supplementary Figure S1) was performed to confirm previously determined threshold. Both cut-offs are slightly different (615.24 vs. 628.5 U/mL), however it does not affect the results.

https://doi.org/10.1038/s41598-022-15726-1
Quantitative values were presented as mean ± standard deviation (SD) or median [interquartile range]. Differences between two independent groups were compared using the Student’s t test or the Mann–Whitney U test. Differences between more than two groups were evaluated using the Kruskal–Wallis ANOVA test. The qualitative parameters are given as numbers with percentages and were evaluated using the contingency tables with the χ² test with Yates’s correction. A p-value of less than 0.05 was considered statistically significant. Logistic regression was used to estimate the odds ratio (OR) and confidence interval (CI). The analysis was performed with STATISTICA version 13 (Dell Inc. 2016). The ROC curve analysis was performed by MedCalc version 20.111 (MedCalc Software Ltd, Ostend, Belgium).

**Data availability**

Data generated and analysed during the current study are available in the manuscript and in the supplementary material.

Received: 14 March 2022; Accepted: 28 June 2022
Published online: 13 July 2022

**References**

1. Wu, C.-Y., Yang, H.-Y., Luo, S.-F. & Lai, J.-H. From rheumatoid factor to anti-citrullinated protein antibodies and anti-carbamylated protein antibodies for diagnosis and prognosis prediction in patients with rheumatoid arthritis. *Int. J. Mol. Sci.* 22, 686 (2021).
2. Aletaha, D. et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis. Rheum.* 62, 2569–2581 (2010).
3. McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. *N. Engl. J. Med.* 365, 2205–2219 (2011).
4. Li, S., Yu, Y., Yue, Y., Zhang, Z. & Su, K. Microbial Infection and Rheumatoid Arthritis. *J. Clin. Cell. Immunol.* 4, 174 (2013).
5. Deane, K. D. et al. Genetic and environmental risk factors for rheumatoid arthritis. *Best Pract. Res. Clin. Rheumatol.* 31, 3–18 (2017).
6. Lu, C. et al. The relationship of PADI4_94 polymorphisms with the morbidity of rheumatoid arthritis in Caucasian and Asian populations: a meta-analysis and system review. *Clin. Rheumatol.* 37, 289–296 (2018).
7. Howe, K. L. et al. Ensemble 2021. *Nucl. Acids Res.* 49, D884–D891 (2021).
8. Uhlen, M. et al. Proteomics Tissue-based map of the human proteome. *Science* 347, 1260419 (2015).
9. Kanehisa, M., Sato, Y., Furumichi, M., Morishima, K. & Tanabe, M. New approach for understanding genome variations in KEGG. *Nucleic Acids Res.* 47, D590–D595 (2019).
10. Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. *Nucleic Acids Res.* 28, 27–30 (2000).
11. Mutua, V. & Gershwin, L. J. A review of neutrophil extracellular traps (NETs) in disease: potential anti-NETs therapeutics. *Clin. Rev. Allergy Immunol.* 61, 194–211. https://doi.org/10.1007/s12016-020-08804-7 (2020).
12. Guderud, K. et al. Lack of association among peptidyl arginine deiminase type 4 autoantibodies, PADI4 polymorphisms, and clinical characteristics in rheumatoid arthritis. *J. Rheumatol.* 45(9), 1211–1219 (2018).
13. Karami, J., Aslani, S., Jamshidi, A., Garshasbi, M. & Mahmoudi, M. Genetic implications in the pathogenesis of rheumatoid arthritis; RF, rheumatoid factor; VAS PhGA, visual analog scale physician global assessment; VAS PGA, visual analog scale patient global assessment. Significant values are in [bold].

### Table 1. Characteristics of the subjects. Data are presented as mean ± SD; median [interquartile range] or number (%). Abbreviations: ACPA, anti-citrullinated protein antibodies; CRP, C-reactive protein; PAD4, peptidyl arginine deiminase type 4; ESR, erythrocyte sedimentation rate; HC, healthy controls; RA, patients with rheumatoid arthritis; RF, rheumatoid factor; VAS PhGA, visual analog scale physician global assessment; VAS PGA, visual analog scale patient global assessment.

| Characteristics | RA overall n=122 | HC n=25 | p-value |
|-----------------|-----------------|--------|---------|
| Age (years)     | 52 ± 12.3       | 53 ± 8.4 | 0.9     |
| Females; n (%)  | 103 (84.4)      | 18 (72)  | 0.23    |
| Disease duration (years) | 10 [3–16]       | n/a     | n/a     |
| RF-positive; n (%) | 82 (67.2)       | none    | n/a     |
| ACPA-positive; n (%) | 104 (85.2)      | none    | n/a     |
| anti-PAD4-positive; n (%) | 68 (55.7)       | 2 (8)   | <0.0001 |
| ESR [mm/h]      | 26 [8–57.5]     | 15.5 [7–20] | 0.001   |
| CRP [mg/dl]     | 8.54 [5.53–19.12] | 0.59 [0.2–1.95] | <0.0001 |
| DAS28            | 3.95 ± 1.55     | n/a     | n/a     |
| Swollen joints  | 1 [0–4]         | n/a     | n/a     |
| Tender joints   | 3 [1–6]         | n/a     | n/a     |
| VAS PGA          | 27 [9–61]       | n/a     | n/a     |
| VAS PhGA        | 20 [7–49]       | n/a     | n/a     |

https://doi.org/10.1038/s41598-022-15726-1
18. Costenbader, K. H., Chang, S.-C., De Vivo, I., Plenge, R. & Karlson, E. W. Genetic polymorphisms in PTPN22, PADI4, and CTLA-4 and risk for rheumatoid arthritis in two longitudinal cohort studies: evidence of gene-environment interactions with heavy cigarette smoking. *Arthritis. Res. Ther.* 10, R52 (2008).
19. Harney, S. M. J. et al. Genetic and genomic studies of PADI4 in rheumatoid arthritis. *Rheumatology* 44, 869–872 (2005).
20. Kochi, Y. et al. PADI4 polymorphism predisposes male smokers to rheumatoid arthritis. *Ann. Rheum. Dis.* 70, 512–515 (2011).
21. Barton, A. et al. A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population. *Arthritis. Rheum.* 50, 1117–1121 (2004).
22. Poot, G. et al. Genetic background of anticyclic citrullinated peptide autoantibody production in Hungarian patients with rheumatoid arthritis. *Ann. N. Y. Acad. Sci.* 1110, 23–32 (2007).
23. Machiela, M. J. & Chanock, S. J. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. *Bioinformatics* 31, 3555–3557 (2015).
24. Reyes-Castillo, Z. et al. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features. *Clin. Exp. Immunol.* 182, 119–131 (2015).
25. Martinez-Prat, L. et al. Autoantibodies to protein-arginine deiminase (PADI) 4 in rheumatoid arthritis: immunological and clinical significance, and potential for precision medicine. *Expert Rev. Clin. Immunol.* 15, 1073–1087 (2019).
26. Kolarz, B., Ciesla, M., Dryglewska, M. & Majdan, M. Peptidyl arginine deiminase type 4 gene promoter hypo-methylation in rheumatoid arthritis. *J. Clin. Med.* 9, 2049 (2020).
27. Halvorsen, E. H. et al. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity. *Ann. Rheum. Dis.* 67, 414–417 (2008).
28. Demoruelle, M. K. et al. Anti-peptidylarginine deiminase–4 antibodies at mucosal sites can activate peptidylarginine deiminase–4 enzyme activity in rheumatoid arthritis. *Arthritis Res. Ther.* 23, 163 (2021).
29. Navarro-Millán, I. et al. Association of anti-peptidyl arginine deiminase antibodies with radiographic severity of rheumatoid arthritis in African Americans. *Arthritis Res. Ther.* 18, 241 (2016).
30. Takizawa, Y. et al. Peptidylarginine deiminase 4 (PADI4) identified as a conformation-dependent autoantigen in rheumatoid arthritis. *Scand. J. Rheumatol.* 34, 212–215 (2005).
31. Harris, M. L. et al. Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. *Arthritis Rheum.* 58, 1958–1967 (2008).
32. Aggarwal, R., Liao, K., Nair, R., Ringold, S. & Costenbader, K. H. Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. *Arthritis Rheum.* 61, 1472–1483 (2009).
33. Kolarz, B., Ciesla, M., Rosenthal, A. K., Dryglewska, M. & Majdan, M. The value of anti-CarP and anti-PAD4 as markers of rheumatoid arthritis in ACPA/RF negative rheumatoid arthritis patients. *Ther. Adv. Musculoskelet. Dis.* 13, 1759720X21989868 (2021).

**Author contributions**
Conceptualization: M.C. and B.K.; methodology: M.C.; writing original draft preparation: M.C.; writing review and editing: B.K. and D.D.K.; supervision: D.D.K. All authors have read and agreed to the published version of the manuscript.

**Competing interests**
The authors declare no competing interests.

**Additional information**
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-15726-1.

**Correspondence** and requests for materials should be addressed to M.C.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2022